Publications by authors named "M Bahadir Inan"
Article Synopsis
- Checkpoint inhibitors like atezolizumab are important immunotherapy drugs used to treat various cancers by targeting immune checkpoints.
- This study focused on producing atezolizumab using a specialized monoclonal cell line from Chinese hamster ovary cells, aiming to establish a reliable production process.
- After growing the cells in a bioreactor and purifying the antibody through chromatography, researchers compared the produced atezolizumab with the commercially available version to evaluate its characteristics.
Addressing the critical shortage of mental health resources for effective screening, diagnosis, and treatment remains a significant challenge. This scarcity underscores the need for innovative solutions, particularly in enhancing the accessibility and efficacy of therapeutic support. Embodied agents with advanced interactive capabilities emerge as a promising and cost-effective supplement to traditional caregiving methods.
View Article and Find Full Text PDFChymosin is an enzyme used to coagulate milk, in the cheese industry. This study aimed to increase recombinant production of the chymosin in Pichia pastoris by determining the optimum copy number and overproduction of a Protein Disulfide Isomerase (PpPDI) chaperon protein. Bos taurus chymosin was expressed under the control of a mutant ADH2 promoter.
View Article and Find Full Text PDFBackground: This study aims to evaluate the relationship between volumetric measurements of residual tumor via magnetic resonance imaging (MRI) and pathologic complete response (pCR) in rectal cancer patients undergoing neoadjuvant chemoradiotherapy (nCRT).
Methods: Patients with locally advanced rectal cancer who had pelvic MRI for clinical staging and completed nCRT followed by radical resection were included. Two experienced radiologists measured tumor volume on MRI obtained before and after nCRT.
Article Synopsis
- Chronic spontaneous urticaria (CSU) negatively impacts patients' quality of life, and omalizumab is recommended for cases resistant to antihistamines; the Urticaria Activity Score-7 (UAS-7) measures disease severity.* -
- A study compared the long-term effectiveness and side effects of two doses (150 mg and 300 mg) of omalizumab in 108 CSU patients over 60 months, finding no significant differences in disease scores or adverse events between groups.* -
- The research concluded that starting with a 150 mg dose is adequate for CSU treatment, with an option to increase to 300 mg if needed, offering a potentially safer and more